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ABSTRACT
BACKGROUND AND PURPOSE: The structural MR imaging correlates of cognitive impairment in multiple sclerosis are still debated. This
study assessed lesional and atrophy measures of white matter and gray matter involvement in patients with MS acquired in 7 European
sites to identify the MR imaging variables most closely associated with cognitive dysfunction.
MATERIALS ANDMETHODS: Brain dual-echo, 3D T1-weighted, and double inversion recovery scans were acquired at 3T from 62 patients
with relapsing-remitting MS and 65 controls. Patients with at least 2 neuropsychological tests with abnormal ﬁndings were considered
cognitively impaired. Focal WM and cortical lesions were identiﬁed, and volumetric measures from WM, cortical GM, the hippocampus,
and deep GM nuclei were obtained. Age- and site-adjusted models were used to compare lesion and volumetric MR imaging variables
between patients with MS who were cognitively impaired and cognitively preserved. A multivariate analysis identiﬁed MR imaging
variables associated with cognitive scores and disability.
RESULTS: Twenty-three patients (38%) were cognitively impaired. Compared with those with who were cognitively preserved, patients
with MS with cognitive impairment had higher T2 and T1 lesion volumes and a trend toward a higher number of cortical lesions. Signiﬁcant
brain, cortical GM, hippocampal, deep GM nuclei, andWM atrophy was found in patients withMSwith cognitive impairment versus those
who were cognitively preserved. Hippocampal and deep GM nuclei atrophy were the best predictors of cognitive impairment, while WM
atrophy was the best predictor of disability.
CONCLUSIONS: Hippocampal and deep GM nuclei atrophy are key factors associated with cognitive impairment in MS. These MR
imaging measures could be applied in a multicenter context, with cognition as clinical outcome.
ABBREVIATIONS: CI cognitively impaired; CL cortical lesion; CP cognitively preserved; DIR double inversion recovery; EDSS Expanded Disability Status
Scale; HC healthy controls; LV lesion volumes; WCSTWisconsin Card Sorting Test
Cognitive impairment is a frequent finding in patients withmultiple sclerosis, with 40%–70% of patients showing cogni-
tive deficits.1 The most affected domains are attention, informa-
tion-processing speed, executive functions, and memory and
visuospatial abilities.1 Given its dramatic effect on the activities of
patients’ daily lives, there is a critical need to define the patho-
physiologic mechanisms of cognitive impairment in MS, to de-
velopmarkers for itsmonitoring, and to identify valid therapeutic
strategies.
Many studies tried to characterize the structural MR imaging
correlates of cognitive impairment in patients withMS. T2 andT1
lesion volumes were found to be generally higher in patients with
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MS who were cognitively impaired (CI) than in those who were
cognitively preserved (CP),2-5 and poor performance on a given
neuropsychological test correlated with the presence of lesions in
relevant WM tracts.2,4,6 GM damage was also variously related to
cognitive impairment in these patients. In particular, higher cor-
tical lesion (CL) volume on double inversion recovery (DIR) se-
quences,7,8 reduced neocortical and total GM volume,7,9 and
structural abnormalities within strategic GM regions, such as the
thalamus, putamen, and hippocampus, were related to the pres-
ence and severity of cognitive symptoms.10-13
Despite the clear association between isolated measures of
structural CNS damage (eg, WM lesion volume or GM volume)
and cognitive performance, when multiparametric models were
applied to identify the imaging correlates of cognitive impair-
ment, conflicting results have been obtained, with some studies
identifying a prominent contribution ofWMdamage5,14 and oth-
ers underpinning the relevance of cortical or deep GM nuclei
involvement.3,9,13 Additionally, composite models explaining
cognitive impairment have only been tested at single sites, in se-
lected groups of patients.13 Lesional and volumetric MR imaging
measures of WM and GM damage might be used as outcome
measures for disease-monitoring purposes, both in observational
and treatment studies. However, to test the utility of these mea-
sures as objective imaging biomarkers of cognitive impairment, a
validation of such multiparametric models in a multicenter set-
ting is needed.
Here, we hypothesized that GM loss might be the most rele-
vant contributor of cognitive impairment in MS. To test our hy-
pothesis, we characterized the structuralMR imaging correlates of
cognitive impairment in a group of patients with MS acquired in
7 European sites by analyzing lesional and atrophy measures of
WM and GM involvement, and we identified the set of MR imag-
ing variables most closely associated with cognitive dysfunction.
MATERIALS AND METHODS
Ethics Committee Approval
Local ethics approval was obtained at all sites; all subjects gave
written informed consent.
Subjects
Subjects were recruited from January 2009 toMay 2012 as part of
a project on imaging correlates of cognitive impairment in MS at
7 European centers. The results of regional analysis of GM and
WMdamage by using surface-based15 and voxelwise techniques16
have been previously reported.
All subjects had to be between 20 and 65 years of age. Patients
had to have a diagnosis of relapsing-remittingMS,17 no relapse or
corticosteroid treatment within the month before scanning, and
no history of psychiatric conditions, including major depression.
The final dataset included 62 patients with MS (22/40 men/
women; mean age, 39.5  8.5 years; mean disease duration, 8.2
years [range, 2–33 years]; median Expanded Disability Status
Scale [EDSS] score, 2.0 [range, 0.0–6.0]) and 65 healthy controls
(HC) (27/38 men/women; mean age, 35.8  9.4 years) (On-line
Table). Sex did not differ between HC and patients withMS (P
.7), whereas HC were younger than patients with MS (P .006).
Thus, age was included as a nuisance covariate in all statistical
models.
Clinical and Neuropsychological Assessment
Within 48 hours from the MR imaging acquisition, patients with
MS underwent a neurologic evaluation, with an EDSS rating and
a neuropsychological assessment performed at each site by an
experienced neuropsychologist unaware of the MR imaging re-
sults, using validated translations of the neuropsychological tests.
Cognitive performance was assessed by using the Brief Repeatable
Battery ofNeuropsychological Tests,18 including the Selective Re-
minding Test to assess verbal memory; the 10/36 Spatial Recall
Test to assess visuospatial memory; the Symbol Digit Modalities
Test and the Paced Auditory Serial Addition Test 2 seconds and 3
seconds to assess attention and information processing speed; and
the Word List Generation test to assess verbal fluency. As previ-
ously described,19 z scores for each of the previous domains and a
global z score of cognitive function (obtained by averaging z
scores of all tests) were calculated.
In addition, the Wisconsin Card Sorting Test (WCST) was
administered to evaluate executive functions.20 Performance on
the WCST was evaluated by computing scores related to the total
errors, the number of perseverative errors, and the number of
perseverative responses.20 Patients with a score 2 SDs below
normative values in at least 1 of these measures were considered
impaired on the WCST.
Patients with at least 2 abnormal test results (defined as a score
2 SDs below the normative value provided by Boringa et al21 for
the Brief Repeatable Battery of Neuropsychological Tests and by
Heaton20 for the WCST) were considered CI, as previously
described.16
MR Imaging Acquisition
With 3T scanners (Centers I and VI: Signa; GE Healthcare, Mil-
waukee, Wisconsin; Centers II, III, and IV: Magnetom Trio; Sie-
mens, Erlangen, Germany; Centers V and VII: Intera; Philips
Healthcare, Best, the Netherlands), centers performed the follow-
ing brain sequences: 1) dual-echo TSE: TR  4000–5380 ms;
TE1 10–23ms; TE2 90–102ms; echo-train length 5–11; 44
contiguous, 3-mm-thick axial sections parallel to the anterior/
posterior commissure plane; matrix 256 192; FOV 240
180 mm2 (rectangular FOV  75%); 2) 3D T1-weighted scan:
TR  5.5–8.3 ms (for GE Healthcare/Philips Healthcare scan-
ners) or 1900–2300 ms (for Siemens scanners); TE 1.7–3.0 ms;
flip angle 8°–12°; 176–192 sagittal sections with thickness 1
mm and in-plane resolution  1  1 mm2; 3) double inversion
recovery sequence: TR 7500–16,000 ms; TE 25–317 ms; TI1
 325–500ms; TI2 2100–3870ms; echo-train length 10–13;
44 contiguous, 3-mm-thick axial sections parallel to the anterior/
posterior commissure plane; matrix 256 192; FOV 240
180 mm2 (rectangular FOV 75%), apart from Center I, which
performed a 3D acquisition with 140 sagittal sections with thick-
ness 1.2 mm; matrix 224 224; FOV 220 220 mm2.
MR Imaging Analysis
Center V performed central analysis of MR imaging scans. WM
and GM lesions were identified by a radiologist (D.D., with 10
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years of experience) supervised by a neurologist (M.A.R., with 20
years of experience). Brain T2-hyperintense and T1-hypointense
lesion volumes (LV) were measured on dual-echo and 3D T1-
weighted scans, respectively, by using a local thresholding seg-
mentation technique (Jim 6.0 software; http://www.xinapse.com/
home.php). DIR scans fromCenter I were first reformatted to the
axial orientation and resampled to 3-mm section thickness, to
standardize evaluation of DIR lesions across sites. Then, DIR im-
ages were used to count CLs according to consensus recommen-
dations.22 CLs included the following: 1) lesions confined to the
cortical ribbon without involving the underlying subcorticalWM
(pure intracortical lesions), and 2) mixed WM/GM lesions (type
I) with a prominent extension within the GM (75%). Attention
was paid to the exclusion of artifacts. Pure, mixed WM/GM, and
total DIR LV were calculated by using Jim software.
Normalized brain volume, normalized GM volume, normal-
ized cortical GM volume, and normalized WM volume were
measured on 3D T1-weighted scans by using FSL SIENAX
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/SIENA) after refilling of
T1-hypointense lesions.23 Automatic segmentation of the thal-
amus, caudate, putamen, pallidum, hippocampus, amygdala,
and accumbens was performed on 3D T1-weighted scans by
using the FMRIB Integrated Registration and Segmentation
Tool (FIRST; http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST) soft-
ware (Fig 1).24 The volume of these structures was multiplied
by the head-normalization factor derived from SIENAX.
Statistical Analysis
Demographic and clinical characteristics, together with lesional
and volumetric MR imaging variables, were reported as means
and ranges, or frequencies and percentages, for continuous and
categoric variables, respectively. Brain T2 and T1 LV were log-
transformed due to their skewed distribution. Given the similar
behavior of right and left deepGMnuclei, deepGMvolumeswere
averaged across hemispheres before statistical analysis. This pro-
cess avoided multicollinearity and reduced the number of com-
parisons. The normalized volume of deep GM nuclei (ie, the sum
of the thalamus, caudate, putamen, pallidum, amygdala, and ac-
cumbens) was also obtained. Between-center heterogeneity of
MR imaging variables was tested by us-
ing ANOVA models for continuous
variables and Pearson 2 tests for cate-
goric variables (apart fromCL numbers,
which were entered into negative bino-
mial models).
Comparisons between HC and pa-
tients with MS and between HC and pa-
tients with MS who were CP and CI of
lesional and volumetric MR imaging
quantities were performed by using age-
adjusted generalized linear random-ef-
fect models, accounting for clustering
(ie, subjects within the recruitment site)
by using random intercepts and an un-
structured covariance matrix.
Univariate correlations between
clinical, neuropsychological, and le-
sion/volumetric MR imaging variables were also assessed by
using generalized linear random-effects models, accounting
for clustering by using random intercepts and an unstructured
covariance matrix, adjusting for age. The effect size of correla-
tions was reported by using standardized regression coeffi-
cients. The same modeling strategy was used to identify MR
imaging variables independently associated with cognitive and
EDSS scores by using a stepwise variable selection. Variables
were selected by using a significance level of .10 for entry into
the model and a significance level of .05 to remain in the mul-
tivariate model.
A P value  .05 was considered statistically significant (SAS
Release 9.1.3 software; SAS Institute, Cary, North Carolina). All
results were adjusted for multiple comparisons by using the false
discovery rate approach.25
RESULTS
Demographic, Clinical, and Neuropsychological Measures
The On-line Table summarizes the main demographic and clini-
cal characteristics of the study subjects. No site heterogeneity was
found for sex and disease duration, while age and EDSS were
heterogeneous among sites (On-line Table).
Twenty-three (37%) patients with MS were CI. The domains
most frequently involved were the following: attention and infor-
mation-processing speed (43%), verbal memory (27%), spatial
memory (21%), and fluency (16%). All patients impaired on the
WCST (n 15) were also classified as CI on the Brief Repeatable
Battery ofNeuropsychological Tests. ComparedwithCP patients,
those with MS who were CI were significantly older (P  .007),
whereas no differencewas found for sex (P .2), EDSS score (P
.3), disease duration (P  .4), and education (mean years of
education, 13.7 3.1 years in CPMS and 13.5 3.4 years in CI
MS, P  .8).
Lesion Findings
There was no significant between-site heterogeneity for T2 (P 
.17), T1 (P .22), and DIR (P .09) LV (Table 1). The number
of CLs was significantly heterogeneous among sites (P .001 for
total and pure CLs, P  .07 for mixed CLs). Compared with CP
FIG 1. Illustrative examples of segmentation of cortical gray matter volume (in red-yellow), deep
gray matter volume (in green), and lesions (in blue) in patients with multiple sclerosis without (A)
and with (B) cognitive impairment. Images are in radiologic convention.
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patients, those with MS who were CI had higher T2 and T1 LV,
whereas DIR LV and the number of CLs did not differ between
groups (Table 1).
Volumetric MR Imaging Findings
Normalized brain volume, normalized GM volume, normalized
cortical GM volume, and normalized white matter volume were
significantly heterogeneous across sites (P  .001–.04), while
this was not the case in deep GM nuclei volumes, apart from the
amygdala (P .001). Volumes of deep GM nuclei were similar to
those obtained in previous studies.26,27 All structures were atro-
phied in patients with MS compared with HC (P .001) and in
patients with MS who were CI versus CP (Table 1).
Analysis of Correlation
T2 LV and T1 LV were significantly correlated with global and
partial cognitive scores, but not with EDSS (Table 2). Lower nor-
malized brain volumewas associatedwithworse neuropsycholog-
ical scores and higher disability. When looking at brain tissue
compartments (ie, WM and GM), we found that EDSS was cor-
relatedwith normalizedwhitematter volume,whereas the highest
correlation with the global cognitive score was found with de-
creased normalized cortical GMvolume (Table 2). Decreased vol-
umes of all deep GM nuclei and the hippocampus were signifi-
cantly associated with global and attention neuropsychological
scores. Lower putamen and pallidum volumes were correlated
with higher EDSS scores. There were no significant correlations
between MR imaging measures and disease duration, verbal
memory, or fluency z scores. Furthermore, no correlation was
found between CLs and clinical/neuropsychological measures.
The multivariate analysis retained average hippocampal vol-
ume (explained variance 15%, P .0002) as the best predictor
of global cognitive z scores, normalized volume of deep GM nu-
clei (explained variance 19%, P .001) as the best predictor of
Table 1: Lesion and volumetric MRI ﬁndings in healthy controls and patients with MS, ﬁrst considered as a whole and then divided into
patients who are cognitively preserved and cognitively impaired
HC MS Pa
Cognitively Preserved
Patients
Cognitively Impaired
Patients Pa
T2 LV (mL) (SD) NA 10.6 (13.9) NA 7.1 (9.6) 16.5 (17.8) .01
T1 LV (mL) (SD) NA 5.5 (5.8) NA 3.6 (3.5) 8.7 (7.6) .01
DIR LV (mL) (SD) NA 0.4 (0.7) NA 0.4 (0.9) 0.4 (0.4) .4
Median CL (No.) (range) NA 3 (0–33) NA 2.0 (0–33) 6.0 (1–16) .5b
Median pure CL (No.) (range) NA 1 (0–14) NA 0.5 (0–14) 1.5 (0–11) .8b
Median mixed CL (No.) (range) NA 2 (0–19) NA 1.0 (0–19) 4.0 (0–9) .9b
NBV (mL) (SD) 1533 (79) 1436 (145) .001 1460 (98) 1395 (113) .006
NGMV (mL) (SD) 826 (56) 776 (67) .0002 793 (68) 748 (57) .02
NCGMV (mL) (SD) 638 (48) 599 (53) .0004 612 (55) 578 (43) .02
NWMV (mL) (SD) 706 (40) 659 (68) .001 667 (54) 645 (88) .03
Total normalized deep GM volume (mL) (SD) 28.1 (1.7) 24.7 (3.1) .001 25.8 (2.4) 23.0 (3.5) .001
Average normalized thalamus volume (mL) (SD) 11.1 (0.7) 9.7 (1.3) .001 10.1 (1.0) 9.0 (1.4) .0007
Average normalized caudate volume (mL) (SD) 5.0 (0.5) 4.4 (0.7) .001 4.5 (0.6) 4.1 (0.7) .02
Average normalized putamen volume (mL) (SD) 6.8 (0.6) 6.1 (0.9) .001 6.5 (0.7) 5.5 (0.9) .001
Average normalized pallidum volume (mL) (SD) 2.5 (0.3) 2.2 (0.2) .001 2.3 (0.1) 2.1 (0.3) .05
Average normalized hippocampus volume (mL) (SD) 5.3 (0.4) 4.8 (0.6) .001 5.0 (0.5) 4.5 (0.7) .004
Average normalized amygdala volume (mL) (SD) 1.8 (0.3) 1.6 (0.3) .001 1.7 (0.3) 1.5 (0.3) .05
Average normalized accumbens volume (mL) (SD) 0.7 (0.1) 0.6 (0.1) .004 0.6 (0.1) 0.5 (0.1) .01
Note:—NA indicates not applicable; NBV, normalized brain volume; NGMV, normalized GM volume; NCGMV, normalized cortical GM volume; NWMV, normalizedWM volume.
a Age- and site-adjusted linear mixed-effect model with random intercept for recruitment site.
b Age-adjusted negative binomial mixed-effect model with random intercept for recruitment site (false discovery rate–corrected).
Table 2: Correlations between lesion and volumetric MRI measures of WM and GM with clinical and neuropsychological variables (age-
adjusted linear mixed-effect model with random intercept for recruitment site, false discovery rate–corrected)a
MRI Measure
Global Cognitive
Z Score
Attention
Z Score
Visual Memory
Z Score
Executive Functions
(WCSTpr) EDSS
T2 LV 0.35 (.01) 0.33 (.008) 0.34 (.03) 0.25 (.06) NS
T1 LV 0.31 (.02) 0.31 (.01) 0.33 (.03) 0.28 (.05) NS
NBV 0.44 (.01) 0.44 (.001) 0.35 (.03) NS 0.33 (.01)
NGMV 0.36 (.01) 0.31 (.01) NS NS NS
NCGMV 0.42 (.01) 0.36 (.01) NS NS NS
NWMV 0.37 (.01) 0.40 (.004) 0.35 (.03) NS 0.35 (.008)
Total normalized deep GM volume 0.40 (.001) 0.47 (.001) 0.33 (.04) NS 0.29 (.03)
Average normalized thalamus volume 0.36 (.002) 0.41 (.0005) 0.30 (.05) NS NS
Average normalized caudate volume 0.40 (.001) 0.50 (.001) NS NS NS
Average normalized putamen volume 0.40 (.001) 0.46 (.0001) 0.37 (.03) NS 0.30 (.03)
Average normalized pallidum volume 0.25 (.03) 0.34 (.003) NS NS 0.35 (.01)
Average normalized hippocampus volume 0.39 (.001) 0.34 (.003) NS NS NS
Average normalized amygdala volume 0.33 (.01) 0.33 (.01) NS NS NS
Average normalized accumbens volume 0.32 (.009) 0.36 (.003) NS NS NS
Note:—NS indicates not signiﬁcant;WCSTpr,Wisconsin Card Sorting Test, number of perseverative responses; NBV, normalized brain volume; NGMV, normalized GM volume;
NCGMV, normalized cortical GM volume; NWMV, normalized WM volume.
a Correlations are reported as standardized coefﬁcients (to include size effect), and P values are reported in parentheses.
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attention z scores, normalized brain volume (explained vari-
ance  10%, P  .006) as the best predictor of visual memory z
scores, and normalized WM volume (explained variance  8%,
P .008) as the best predictor of EDSS scores.
DISCUSSION
This is one of the first multicenter studies characterizing lesion
and volumetricMR imaging correlates of cognitive impairment in
patients withMS, to our knowledge. More severe damage of both
WM and GM compartments was found in patients with MS who
were CI compared with CP, despite similar levels of clinical dis-
ability. WM lesion volume and GM atrophy were both correlated
with the severity of cognitive deficits, supporting the notion that
different substrates contribute to cognitive dysfunction. How-
ever, onmultivariate analysis,measures of GMvolumewere iden-
tified as the best correlate of global cognitive impairment. Overall,
our results suggest that volumes of the hippocampus and deep
GMnucleimay be reliable biomarkers of cognitive impairment in
MS and might be used in multicenter observational or treatment
studies.
In agreement with the results of previous studies,2-4,18 we
found that both T2 and T1 LV were higher in patients with MS
who were CI than CP. This finding seems to indicate that discon-
nection, caused by focal WM damage, may represent one of the
factors contributing to the development of cognitive impairment
in MS.4 Hyperintensities on T2-weightedMR imaging have a rel-
atively low pathologic specificity because they relate to a variety of
processes, while T1 hypointensities seem to be more closely asso-
ciated with severe demyelination and axonal loss.28 The signifi-
cantly higher T1 LVwe found in CI versus CPMS suggest that not
only the extent but also the severity of damage within MS lesions
might be relevant in determining cognitive decline in these
patients.
Contrary to our expectations, we found only a nonsignificant
trend toward a higher number of CLs in patients with MS who
were CI compared with CP. This is in contrast to results of previ-
ous studies,7,8 which reported associations between the number
and volume of CLs and cognitive impairment. At least 2 factors
could help explain this discrepancy. First, DIR sequences can be
challenging to standardize across scanners, and in this study, they
were acquired with different geometry (3D versus 2D) and pa-
rameters across sites. These differences may have contributed to
the heterogeneity of CL counts and volumes seen across sites. In
comparison, dual-echo and 3D T1-weighted scans were acquired
with a relatively standardized protocol, and T2 and T1 LV were
accordingly similar among sites. Second, DIR sequences are more
prone to artifacts than T2- andT1-weighted sequences, which can
impact the detection of CLs.22
GMatrophy can also contribute to cognitive symptoms inMS.
In line with previous studies, we found significantly reduced cor-
tical, hippocampal, and deep GM volumes in patients with MS
who were CI compared with CP. Reduced neocortical vol-
ume2,3,7,9 and a widespread pattern of regional GM atro-
phy15,16,29 have been frequently associated with cognitive impair-
ment inMS, as also shown by a previous investigation of the same
patient cohort.16 GMpathology is known to be substantially pres-
ent in MS from the earliest stages of the disease and is strongly
associated with CI not only in cross-sectional but also in longitu-
dinal studies.30 GM pathology has traditionally been thought to
occur secondary to injury from focal WM lesions (so-calledWal-
lerian degeneration), but recent studies have convincingly shown
that cortical inflammatory pathology from subpial demyelination
also plays a critical role.31,32
Another interesting result was the widespread volume loss we
found in CI compared with CP MS in deep GM nuclei and the
hippocampus. This finding confirms a previous voxelwise inves-
tigation of the same cohort,16 which showed that hippocampal
atrophy was among the bestMR imaging variables discriminating
patients with MS who were CI from those who were CP. The
thalamus, hippocampus, and striatal structures represent conver-
gence points across multiple cortical, limbic, brain stem, and cer-
ebellar systems and have a key role for efficient information pro-
cessing.33 Because a decrease in information-processing speed is
one of the main features of cognitive impairment in MS,34 dam-
age to these structures has frequently been linked to cognitive
impairment.10,11,13 Remarkably, even if we found a significant
correlation between thalamic atrophy and CI, our multivariate
model indicated a major role of the hippocampus in explaining
cognitive deficits. This finding partially conflicts with findings in
previous studies.10,11 However, these studies did not perform a
direct comparison of the relative contribution of thalamic and
hippocampal atrophy with cognitive impairment. On the other
hand, hippocampal injury has been associated not only with
memory deficits35,36 but also with impaired visuospatial or verbal
memory abilities.12,36
Our results indicated that most cognitive scores were corre-
latedwith higher T2 andT1LV. This result was not the case for the
EDSS, which did not correlate with lesion extent in univariate
models. Moreover, univariate correlations showed that cognitive
and clinical disability scores were associatedwith decreased global
and deep GM volumes. Most interesting, multivariate correla-
tions showed that cognitive scores were best predicted by hip-
pocampal and deep GM loss, whereas WM loss was the most
significant contributor to the EDSS score. Although we cannot
exclude GM volume loss of critical cortical regions (eg, the motor
cortex) also contributing to the EDSS score, the high relevance to
clinical disability from normalized WM volume suggests that de-
myelination and the consequent disruption ofWMpathways play
an important role in explaining clinical (and in particular, loco-
motor) disability. Conversely, cortical, hippocampal, and deep
GM nuclei atrophy in patients with MS was more closely associ-
ated with cognitive scores thanWM atrophy. This result is in line
with several previous studies,2,3,9 including a previous voxelwise
investigation of the same cohort.16 This similarity suggests that
the findings hold across a wide spectrum of the MS population.
Moreover, because normalized cortical GM volume and normal-
ized volume of deep GM nuclei predict cognitive deterioration
with time,27,37 theymight be used as reliable outcomemeasures in
multicenter observational or treatment studies of cognitive im-
pairment in MS.
Our study has limitations. First, the DIR acquisition protocol
was not fully standardized across sites. Second, multicenter, lon-
gitudinal observations, including larger cohorts of patients with
MS at different stages of the disease, are needed to validate our
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findings and to define how the development of GM and WM
damage contributes to the evolution of cognitive impairment
with time. Third, clinical disability was measured by using the
EDSS, which is strongly weighted toward locomotor dysfunction.
Composite scores (such as the Multiple Sclerosis Functional
Composite) might have provided a more comprehensive evalua-
tion of clinical impairment. Finally, we limited our analysis to a
subset of possible MR imaging variables (lesions and atrophy of
whole-tissue compartments), which are likely to be sensitive to
only some of the pathologic substrates of the disease. Further
studies should assess the added contribution of microstructural
WM damage or intrinsic damage within lesions, for example, by
diffusion tensor imaging or other quantitative MR imaging
techniques.
CONCLUSIONS
Our study shows that GM atrophy is critical for explaining cogni-
tive impairment in MS. If an adequate standardization of MR
imaging acquisition and analysis is performed, lesional and atro-
phy measures of GM and WM might be used as biomarkers in
future multicenter observational and treatment studies of cogni-
tive impairment in MS.
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